Author:
Lotz M,Martel-Pelletier J,Christiansen C,Brandi M-L,Bruyère O,Chapurlat R,Collette J,Cooper C,Giacovelli G,Kanis J A,Karsdal M A,Kraus V,Lems W F,Meulenbelt I,Pelletier J-P,Raynauld J-P,Reiter-Niesert S,Rizzoli R,Sandell L J,Van Spil W E,Reginster J-Y
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology
Reference85 articles.
1. Osteoarthritis: an update with relevance for clinical practice;Bijlsma;Lancet,2011
2. Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. 2010. http://www.ema.europa.eu (accessed 19 Sept 2012).
3. Food and Drug Administration. Guidance for industry. Clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis. 2011. http://www.fda.gov (accessed 12 Jun 2012).
4. Imaging techniques in osteoarthritis;Hunter;PM&R,2012
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework;Atkinson;Clin Pharmacol Ther,2001